Cargando…

Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Background and purpose: Muscle loss is a significant indicator of cancer cachexia and is associated with a poor prognosis in cancer patients. Given the absence of comparable studies, the current retrospective study sought to examine the correlation between the total masseter muscle volume (TMMV) bef...

Descripción completa

Detalles Bibliográficos
Autores principales: Pehlivan, Umur Anil, Somay, Efsun, Yilmaz, Busra, Besen, Ali Ayberk, Mertsoylu, Huseyin, Selek, Ugur, Topkan, Erkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648120/
https://www.ncbi.nlm.nih.gov/pubmed/37959329
http://dx.doi.org/10.3390/jcm12216863
_version_ 1785135265283571712
author Pehlivan, Umur Anil
Somay, Efsun
Yilmaz, Busra
Besen, Ali Ayberk
Mertsoylu, Huseyin
Selek, Ugur
Topkan, Erkan
author_facet Pehlivan, Umur Anil
Somay, Efsun
Yilmaz, Busra
Besen, Ali Ayberk
Mertsoylu, Huseyin
Selek, Ugur
Topkan, Erkan
author_sort Pehlivan, Umur Anil
collection PubMed
description Background and purpose: Muscle loss is a significant indicator of cancer cachexia and is associated with a poor prognosis in cancer patients. Given the absence of comparable studies, the current retrospective study sought to examine the correlation between the total masseter muscle volume (TMMV) before treatment and the survival outcomes in locally advanced nasopharyngeal cancer (LA-NPC) patients who received definitive concurrent chemoradiotherapy (CCRT). Methods: A three-dimensional segmentation model was used to determine the TMMV for each patient by analyzing pre-CCRT magnetic resonance imaging. The optimal TMMV cutoff values were searched using receiver operating characteristic (ROC) curve analyses. The primary and secondary endpoints were the relationship between the pre-CCRT TMMV measures and overall survival (OS) and progression-free survival (PFS), respectively. Results: Ninety-seven patients were included in this study. ROC curve analyses revealed 38.0 cc as the optimal TMMV cutoff: ≤38.00 cc (n = 42) and >38.0 cc (n = 55). Comparisons between the two groups showed that the TMMV>38.0 cc group had significantly longer PFS [Not reached (NR) vs. 28; p < 0.01] and OS (NR vs. 71; p < 0.01) times, respectively. The results of the multivariate analysis demonstrated that the T-stage, N-stage, number of concurrent chemotherapy cycles, and TMMV were independent associates of PFS (p < 0.05 for each) and OS (p < 0.05 for each) outcomes, respectively. Conclusion: The findings of the current retrospective research suggest that pretreatment TMMV is a promising indicator for predicting survival outcomes in LA-NPC patients receiving definitive CCRT.
format Online
Article
Text
id pubmed-10648120
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106481202023-10-30 Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy Pehlivan, Umur Anil Somay, Efsun Yilmaz, Busra Besen, Ali Ayberk Mertsoylu, Huseyin Selek, Ugur Topkan, Erkan J Clin Med Article Background and purpose: Muscle loss is a significant indicator of cancer cachexia and is associated with a poor prognosis in cancer patients. Given the absence of comparable studies, the current retrospective study sought to examine the correlation between the total masseter muscle volume (TMMV) before treatment and the survival outcomes in locally advanced nasopharyngeal cancer (LA-NPC) patients who received definitive concurrent chemoradiotherapy (CCRT). Methods: A three-dimensional segmentation model was used to determine the TMMV for each patient by analyzing pre-CCRT magnetic resonance imaging. The optimal TMMV cutoff values were searched using receiver operating characteristic (ROC) curve analyses. The primary and secondary endpoints were the relationship between the pre-CCRT TMMV measures and overall survival (OS) and progression-free survival (PFS), respectively. Results: Ninety-seven patients were included in this study. ROC curve analyses revealed 38.0 cc as the optimal TMMV cutoff: ≤38.00 cc (n = 42) and >38.0 cc (n = 55). Comparisons between the two groups showed that the TMMV>38.0 cc group had significantly longer PFS [Not reached (NR) vs. 28; p < 0.01] and OS (NR vs. 71; p < 0.01) times, respectively. The results of the multivariate analysis demonstrated that the T-stage, N-stage, number of concurrent chemotherapy cycles, and TMMV were independent associates of PFS (p < 0.05 for each) and OS (p < 0.05 for each) outcomes, respectively. Conclusion: The findings of the current retrospective research suggest that pretreatment TMMV is a promising indicator for predicting survival outcomes in LA-NPC patients receiving definitive CCRT. MDPI 2023-10-30 /pmc/articles/PMC10648120/ /pubmed/37959329 http://dx.doi.org/10.3390/jcm12216863 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pehlivan, Umur Anil
Somay, Efsun
Yilmaz, Busra
Besen, Ali Ayberk
Mertsoylu, Huseyin
Selek, Ugur
Topkan, Erkan
Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title_full Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title_fullStr Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title_full_unstemmed Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title_short Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
title_sort pretreatment masseter muscle volume predicts survival in locally advanced nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648120/
https://www.ncbi.nlm.nih.gov/pubmed/37959329
http://dx.doi.org/10.3390/jcm12216863
work_keys_str_mv AT pehlivanumuranil pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT somayefsun pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT yilmazbusra pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT besenaliayberk pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT mertsoyluhuseyin pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT selekugur pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT topkanerkan pretreatmentmassetermusclevolumepredictssurvivalinlocallyadvancednasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy